Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
14
SUSRF Quote, Financials, Valuation and Earnings
Last price:
$3.41
Seasonality move
:
25.85%
Day range:
$3.41 - $3.41
52-week range:
$3.16 - $16.33
Dividend yield:
0%
P/E ratio:
26.60x
P/S ratio:
1.81x
P/B ratio:
0.38x
Volume:
1K
Avg. volume:
3K
1-year change:
-76.53%
Market cap:
$174M
Revenue:
$83.6M
EPS (TTM):
$0.13
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
-- | -- | -- | -- | -- |
|
BOVNF
BioInvent International AB
|
-- | -- | -- | -- | -- |
|
BRCTF
BioArctic AB
|
-- | -- | -- | -- | -- |
|
CAMRF
Camurus AB
|
-- | -- | -- | -- | -- |
|
HNSBF
Hansa Biopharma AB
|
-- | -- | -- | -- | -- |
|
ORXOY
Orexo AB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
$3.41 | -- | $174M | 26.60x | $0.00 | 0% | 1.81x |
|
BOVNF
BioInvent International AB
|
$3.29 | -- | $216.4M | -- | $0.00 | 0% | 8.69x |
|
BRCTF
BioArctic AB
|
$34.74 | -- | $3.1B | 32.81x | $0.00 | 0% | 16.63x |
|
CAMRF
Camurus AB
|
$69.70 | -- | $4.2B | 53.86x | $0.00 | 0% | 17.95x |
|
HNSBF
Hansa Biopharma AB
|
$2.91 | -- | $290.2M | -- | $0.00 | 0% | 12.08x |
|
ORXOY
Orexo AB
|
$2.60 | -- | $90.2M | -- | $0.00 | 0% | 1.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
0.04% | 1.343 | 0.03% | 2.78x |
|
BOVNF
BioInvent International AB
|
1.54% | -0.944 | 0.53% | 6.82x |
|
BRCTF
BioArctic AB
|
2.31% | 0.968 | 0.18% | 3.14x |
|
CAMRF
Camurus AB
|
2.52% | 0.192 | 0.28% | 9.80x |
|
HNSBF
Hansa Biopharma AB
|
254.41% | 1.407 | 39.58% | 1.00x |
|
ORXOY
Orexo AB
|
171.74% | -0.131 | 97.86% | 1.32x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
$15.8M | $4M | 1.46% | 1.47% | 14.59% | -$1.6M |
|
BOVNF
BioInvent International AB
|
-- | -$14.1M | -37.24% | -37.89% | -4030.98% | -$11.2M |
|
BRCTF
BioArctic AB
|
$12.7M | -$2.6M | 57.61% | 59.48% | -18.55% | -$2.5M |
|
CAMRF
Camurus AB
|
$54.8M | $24.9M | 21.21% | 21.63% | 41.84% | $14.2M |
|
HNSBF
Hansa Biopharma AB
|
$1.1M | -$15.5M | -135.05% | -- | -480.21% | -$9.8M |
|
ORXOY
Orexo AB
|
$11.4M | -$2.2M | -54.08% | -134.37% | -18.19% | $240.6K |
Surgical Science Sweden AB vs. Competitors
-
Which has Higher Returns SUSRF or BOVNF?
BioInvent International AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of -3891.55%. Surgical Science Sweden AB's return on equity of 1.47% beat BioInvent International AB's return on equity of -37.89%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M BOVNFBioInvent International AB-- -$0.21 $73.8M -
What do Analysts Say About SUSRF or BOVNF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioInvent International AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than BioInvent International AB, analysts believe Surgical Science Sweden AB is more attractive than BioInvent International AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 BOVNFBioInvent International AB0 0 0 -
Is SUSRF or BOVNF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioInvent International AB has a beta of 6.936, suggesting its more volatile than the S&P 500 by 593.641%.
-
Which is a Better Dividend Stock SUSRF or BOVNF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioInvent International AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. BioInvent International AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or BOVNF?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are larger than BioInvent International AB quarterly revenues of $348.9K. Surgical Science Sweden AB's net income of $2.1M is higher than BioInvent International AB's net income of -$13.6M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 26.60x while BioInvent International AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.81x versus 8.69x for BioInvent International AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.81x 26.60x $27.7M $2.1M BOVNFBioInvent International AB8.69x -- $348.9K -$13.6M
-
Which has Higher Returns SUSRF or BRCTF?
BioArctic AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of -65.15%. Surgical Science Sweden AB's return on equity of 1.47% beat BioArctic AB's return on equity of 59.48%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M BRCTFBioArctic AB90.84% -$0.10 $214.3M -
What do Analysts Say About SUSRF or BRCTF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than BioArctic AB, analysts believe Surgical Science Sweden AB is more attractive than BioArctic AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 BRCTFBioArctic AB0 0 0 -
Is SUSRF or BRCTF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SUSRF or BRCTF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or BRCTF?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are larger than BioArctic AB quarterly revenues of $14M. Surgical Science Sweden AB's net income of $2.1M is higher than BioArctic AB's net income of -$9.1M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 26.60x while BioArctic AB's PE ratio is 32.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.81x versus 16.63x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.81x 26.60x $27.7M $2.1M BRCTFBioArctic AB16.63x 32.81x $14M -$9.1M
-
Which has Higher Returns SUSRF or CAMRF?
Camurus AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of 33.97%. Surgical Science Sweden AB's return on equity of 1.47% beat Camurus AB's return on equity of 21.63%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M CAMRFCamurus AB91.93% $0.34 $449M -
What do Analysts Say About SUSRF or CAMRF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Camurus AB, analysts believe Surgical Science Sweden AB is more attractive than Camurus AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 CAMRFCamurus AB0 0 0 -
Is SUSRF or CAMRF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.658%.
-
Which is a Better Dividend Stock SUSRF or CAMRF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or CAMRF?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are smaller than Camurus AB quarterly revenues of $59.6M. Surgical Science Sweden AB's net income of $2.1M is lower than Camurus AB's net income of $20.2M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 26.60x while Camurus AB's PE ratio is 53.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.81x versus 17.95x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.81x 26.60x $27.7M $2.1M CAMRFCamurus AB17.95x 53.86x $59.6M $20.2M
-
Which has Higher Returns SUSRF or HNSBF?
Hansa Biopharma AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of -481.29%. Surgical Science Sweden AB's return on equity of 1.47% beat Hansa Biopharma AB's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M HNSBFHansa Biopharma AB34.72% -$0.18 $38.6M -
What do Analysts Say About SUSRF or HNSBF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Hansa Biopharma AB, analysts believe Surgical Science Sweden AB is more attractive than Hansa Biopharma AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 HNSBFHansa Biopharma AB0 0 0 -
Is SUSRF or HNSBF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.764%.
-
Which is a Better Dividend Stock SUSRF or HNSBF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or HNSBF?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are larger than Hansa Biopharma AB quarterly revenues of $3.2M. Surgical Science Sweden AB's net income of $2.1M is higher than Hansa Biopharma AB's net income of -$15.6M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 26.60x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.81x versus 12.08x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.81x 26.60x $27.7M $2.1M HNSBFHansa Biopharma AB12.08x -- $3.2M -$15.6M
-
Which has Higher Returns SUSRF or ORXOY?
Orexo AB has a net margin of 7.74% compared to Surgical Science Sweden AB's net margin of -33.67%. Surgical Science Sweden AB's return on equity of 1.47% beat Orexo AB's return on equity of -134.37%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB57.18% $0.04 $457.4M ORXOYOrexo AB92.89% -$0.12 $29M -
What do Analysts Say About SUSRF or ORXOY?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Orexo AB, analysts believe Surgical Science Sweden AB is more attractive than Orexo AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 ORXOYOrexo AB0 0 0 -
Is SUSRF or ORXOY More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Orexo AB has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.934%.
-
Which is a Better Dividend Stock SUSRF or ORXOY?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or ORXOY?
Surgical Science Sweden AB quarterly revenues are $27.7M, which are larger than Orexo AB quarterly revenues of $12.2M. Surgical Science Sweden AB's net income of $2.1M is higher than Orexo AB's net income of -$4.1M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 26.60x while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 1.81x versus 1.31x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB1.81x 26.60x $27.7M $2.1M ORXOYOrexo AB1.31x -- $12.2M -$4.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
